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Electroconvulsive therapy (ECT) is the longest standing psychiatric treatment available and has unequivocal benefit in severe
depression. However this treatment comeswith a number of side effects such asmemory impairment. On the other hand, Repetitive
Transcranial Magnetic Stimulation (rTMS) is a relatively new form of treatment which has been shown to be efficacious in patients
suffering from a number of psychopathologies, including severe depression, with few reported side effects. Due to its potential
therapeutic efficacy and lack of side effects, rTMS has gained traction in the treatment of depression, with a number of authors
keen to see it take over from ECT. However, it is not clear whether rTMS represents a therapeutic alternative to ECT. This meta-
analysis will therefore compare the “gold standard” treatment for severe depression, with the relatively new but promising rTMS. A
literature search will be performed with the intention to include all randomised clinical trials.The null hypothesis is that there is no
difference in the antidepressant efficacy between the two types of treatment modalities. Statistical analysis of Hamilton Depression
Rating Scale (HDRS) scores will be performed.
1. Introduction
ECT is one of the oldest forms of treatment in psychiatry that
is still used today. A recent systematic review showed “signif-
icant superiority of ECT in all comparisons: ECT versus sim-
ulated ECT, ECT versus placebo, ECT versus antidepressants
in general, ECT versus TCAs, and ECT versus MAOIs” [1].
This confirmed the findings by the UK ECT Review Group
[2] which had found that ECT is an “effective short-term
treatment for depression and is probably more effective than
drug therapy.” The consortium for Research in ECT [3] also
found a strong positive effect for ECT, with remission rates
of 75% after the first two weeks of use, in patients suffering
from acute depressive illness. In a recent study by Kellner
et al. [4] 200 patients diagnosed with unipolar depression
showed better remission rates after bilateral ETC when com-
pared to the control group on Nortriptyline and Lithium.
ECT has also been shown to have positive effects in patients
suffering from severe depression with psychosis, who saw
a remission rate of up to 90%. However, the symptomatic
remission induced by ECT appears to be short-lived [5]. ECT
is also effective, especially when given bilaterally, in themanic
phase of Bipolar Affective Disorder (BPAD) [6, 7]. However,
given the good efficacy of current drug therapy, ECT is
usually limited to patients with specific contraindications
to pharmacological approaches or who are refractory to
pharmacological treatment. In schizophrenia, ECT has been
successfully used in both the acute phase, especially in
patients with catatonic symptoms [8], as well as in chronic
treatment resistant cases [9]. ECT has been used in a number
of other conditions such as Obsessive Compulsive Disorder
[10], Postpartum Psychosis [11], and Parkinson’s disease [12],
with varying degrees of success.
A British Journal of Psychiatry systematic review [13]
showed “an effect in favour of rTMS compared with sham after
2 weeks of treatment, but this was not significant at the 2-
week follow-up.” The study also found that the quality of the
included clinical trials available was low and provided insuf-
ficient evidence to justify the use of rTMS in the treatment
of depression. However an earlier meta-analysis, performed
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on 12 studies comparing HDRS score reduction with rTMS
and sham stimulation, found rTMS to be statistically superior
in the treatment of depression [14]. This was confirmed in
a recent meta-analysis of 34 studies [15], which concluded
that rTMS had a significant effect size difference of 0.55 when
compared to sham stimulation in the treatment of depres-
sion. A recent presentation [16] at the American Psychiatric
Association’s 2013 Annual Meeting, involving a multicentre,
longitudinal, naturalistic, observational study, confirmed that
acute rTMS induced “statistically and clinically meaningful
response and remission” in patients with major depressive
disorder during the acute phase, but more importantly that
the results were maintained at 52 weeks.
One advantage of rTMS over ECT is that the patient
does not need anaesthesia, as well as the fact that seizures
need not be induced. Therefore, rTMS has a much safer
risk profile compared to ECT. Common side effects of rTMS
are headache, twitching of the facial muscles, and auditory
impairments, during the actual treatment. With respect to
severe acute adverse effects, induction of seizures, though
rare, has been known to occur. In the early days of rTMS
accidental seizures were reported and thought to be caused
by overstepping of safety limits now in place. However, in
their report on the safety of rTMS, Rossi et al. conclude that
the risk of rTMS to induce seizures is very low, taking into
account the large amount of study data that exists from 1998
[17]. When adverse effects occur, they are usually mild and
transient and rTMS is considered to be a safe therapeutic
intervention [18]. With respect to adverse cognitive effects,
it is well known that many psychiatric disorders, such as
depression and schizophrenia, have a negative impact on
cognitive functions. However, unlike ECT, rTMS has shown
to improve cognitive functions, including both short as well
as long term memory [19]. In fact, a 2003 study reported that
rTMS patients “demonstrated mild improvement on tests of
working memory and retrograde memory and relative stability
on tests of verbal learning and retention” [20].
2. Materials and Methods
2.1. Hypothesis. This meta-analysis sets out to compare ECT
to the relatively new but promising rTMS, for the manage-
ment of treatment resistant depression. The null hypothesis
being tested is that there is no statistically significant differ-
ence in the antidepressant efficacy between the two types of
treatment modalities.
2.2. Literature Search. A literature searchwas carried outwith
OvidSP using the following resources: MEDLINE (1996 to
JanuaryWeek 5 2013), EBM Reviews—Cochrane Database of
Systematic Reviews (2005 to January 2013), EBM Reviews—
ACP Journal Club (1991 to January 2013), EBM Reviews—
CochraneCentral Register of Controlled Trials (1991–January
2013), Embase (1974 to 2013 Week 06), and PsycINFO (1806
to February Week 1 2013). Search was carried out with a limit
for clinical trials, using theMedical SubjectHeadings (MeSH)
search terms electroconvulsive therapy AND transcranial
magnetic stimulation. The titles of the results were examined
to indicate suitability, followed by a detailed analysis of the
entire study in order to ascertain whether the study met
the established selection criteria. A manual search was then
performed across the reference lists of the identified studies
in order to determine if any additional studies could be
included.
2.3. Selection Criteria. To be included in the meta-analysis
the clinical trial should (1) compare the effect of ECT and
rTMS in the treatment of depression, (2) be a randomised
clinical trial (RCT) published in an English journal, (3) be
conducted on human subjects who are over the age of 18 and
have given informed consent, (4) be prospective with parallel
design, (5) meet ICD-10 or DSM-IV criteria for unipolar
depression or bipolar depression with a current depressive
episode, (6) have HDRS assessed shortly before and after
treatment, and (7) report HDRS score and standard deviation
(SD). A single exclusion criterion was used: comorbid drug
abuse.
2.4. Evaluation of Individual Studies. Each study was meticu-
lously examined and evaluated for study quality. The quality
of the existing literature was judged using Chalmer’s method
[21]. The heterogeneity of study design was also assessed.
2.5. Data Extraction. After the completion of the database
search, the articles were read carefully and a brief summary
of each article was written. The studies were then tabulated
under the following headings: authors, the year of publi-
cation, the number of participants, rTMS or ECT, gender,
psychotropic drugs, the type of rTMS technology used, the
type of ECT technology used, and theHDRSmean and stand-
ard deviation before and after treatment in both groups.
2.6. Statistical Methods. Statistical analyses were done with
SPSS (IBM) and Comprehensive Meta-Analysis software
(Biostat). Changes in HDRS scores in participants were
analysed using paired and independent 𝑡-tests.The effect sizes
were then calculated in the 9 studies, for both rTMS and ECT.
Due to the fact that the sample sizes of the studies were small,
Hedges’ g was used rather than Cohen’s d, in order to reach
a better estimate of effect size [22]. Since one study did not
provide raw scores of HDRS and SD after completion of treat-
ment, instead of the pooled standard deviation, the SD value
obtained before the treatment was used. Since homogeneous
variance is assumed for the effects within a group, this should
have little effect on the end result [23]. An average effect size
was calculated for both groups; effect sizes were summed and
divided by the number of effect sizes. After the effect sizes
were calculated within the groups, a homogeneity analysis
was performed. This type of analysis examines whether the
effect sizes differ significantly. If homogeneity investigation
shows varying effect sizes, it may be justifiable to not pool
together effect sizes and instead make an additional analysis
in order to see if certain characteristics can differentiate the
studies [24]. Three measures of heterogeneity were tested:
𝑄 Test, 𝑧 test, and Radial plot (Galbraith Test). Publication
bias was then ascertained using twomethods: Rosenthal’s File
drawer Method and Rank Correlation. The final step was the
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analysis of combined effect sizes using the Fixed and Random
Effects Models [25].
3. Results
3.1. Participants and Treatment. The meta-analysis included
9 randomised clinical trials published between 2000 and 2011
with a total of 384 participants. Table 1 shows the patient char-
acteristics, including the number of study participants, their
mean age and the duration of depressive episode, the rTMS
and ECT treatment protocols used in the studies, as well as
the diagnosis.With respect to the diagnosis, participants in all
studies had a current diagnosis of Major Depressive Disorder
(MDD). In two studies [26, 27], this included patients with
a history of Bipolar Affective Disorder (BPAD). In two
other studies [20, 28], information was unclear on whether
patients with a previous history of BPAD were included.
Most of the participants in the studies were referred due
to treatment (drug) resistance, which was in fact an actual
selection criterion in two of the studies [28, 29]. Whilst no
reference wasmade to the grade of treatment resistance in the
studies, treatment resistance is a term used to describe cases
of major depressive disorder that do not respond adequately
to adequate courses of at least two antidepressants [30].
3.2. Treatment Characteristics. ECT patients varied with
respect to their psychopharmacological treatment, with two
studies requiring that patients be off treatment before com-
mencement of the study [29, 34]. In two other studies [20, 28],
ECT was used as an add-on to the patient’s psychotropic
treatment, while patients undergoing rTMS were required to
withdraw medications.
3.3. Statistical Analysis
3.3.1. Paired 𝑡-Test for HDRS Improvement. The average im-
provement in HDRS scores for both groups was substantial.
The participants who underwent rTMS had amean reduction
of 9.3 points on theHDRS (SD 4.45, SE 1.48) which was found
to be significant with 𝑡 = 6.274 (𝑃 ≤ 0.0005 at 95% CI).
ECT participants had a mean reduction of 15.42 points on
the HDRS (SD 4.55, SE 1.52) which was also found to be
significant with 𝑡 = 10.18 (𝑃 ≤ 0.0005 at 95% CI).
3.3.2. Independent 𝑡-Test for Difference in Groups. A two sam-
ple 𝑡-test (independent 𝑡-test) showed significant difference
between the rTMS and ECT groups with respect to decrease
in HDRS scores (𝑡 = 2.89, 𝑃 = 0.011).
3.3.3. Effect Size. Bias Corrected (Hedges) Effect Sizes was
calculated in the 9 studies, for both rTMS and ECT. Effect
sizes ranged from 0.56 to 2.83. The mean effect size for rTMS
was 1.33 whilst that for ECT was 2.14. Table 2 summarises
these results.
3.3.4. Independent 𝑡-Test for Difference in Groups with Effect
Size. A two sample 𝑡-test (independent 𝑡-test) showed sig-
nificant difference between the rTMS and ECT groups when













Figure 1: Radial Plot rTMS.
3.3.5. Homogeneity Analysis for rTMS Studies
The 𝑄 Test: 𝑄 = 14.3328 df = 8 𝑃 = 0.0735 𝐼2 =
44.2%.
The 𝑧 Test: Mean 𝑧 = 0.1349 SD 𝑧 = 1.3308.
Radial Plot can be seen in Figure 1.
Homogeneity analysis showed significant heterogeneity
in the combined effect sizes for the rTMS studies; therefore,
additional analysis was performed. An investigation was
carried out to check out the validity of the data from the
studies. However, no obvious reason for heterogeneity was
found, and a decision was made to proceed with the Random
Effect Model for combined Effect Size analysis. A forest plot
can be seen in Figure 2.
3.3.6. Homogeneity Analysis for ECT Studies
The 𝑄 Test: 𝑄 = 10.9267 df = 8 𝑃 = 0.2059 𝐼2 =
26.8%.
The 𝑧 Test: Mean 𝑧 = −0.0435 SD 𝑧 = 1.1678.
Radial Plot can be seen in Figure 3.
Homogeneity analysis showed no significant heterogene-
ity in the combined effect sizes for the ECT studies; therefore,
not any additional analysis was performed. Forest plot can be
seen in Figure 4.
3.3.7. Combined Effect Size for rTMS and ECT Studies. Com-
bined effect sizes for Fixed and Random Effect Models can be
seen in Table 3.
3.3.8. Publication Bias for rTMS Studies
Rosenthal File drawer Method.
Tolerance minimum number = 55.
Estimated number = 282.
Estimated not less than minimum: publication bias
not detected.
Rank Correlation.
𝑧 = 0.1043 𝑃 = 0.4585.
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Table 1: Patient characteristics and treatment protocols.
Study 𝑛 Age Episode duration (mo) Treatment protocol Diagnosis
rTMS ECT rTMS ECT rTMS ECT
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BL: 100% UP + BP









𝑛= number of participants; n.a. = data not available; UP = unipolar depression; BP = bipolar depression;MS =mean number of sessions;MT=motor threshold;
TP = total pulses; UL = unilateral ECT; BL = bilateral ECT.
Table 2: Bias corrected (Hedges) effect sizes for each study.
rTMS ECT
Study Confidence interval Confidence interval
Effect size Standard error Lower Upper Effect size Standard error Lower Upper
Keshtkar 2011 [31] 0.90 0.26 0.39 1.40 2.82 0.32 2.21 3.44
Hansen et al. 2011 [27] 1.31 0.28 0.75 1.87 2.07 0.32 1.45 2.70
Eranti 2007 [32] 0.74 0.30 0.16 1.33 2.83 0.43 1.99 3.66
Rosa et al. 2006 [29] 1.61 0.36 0.89 2.32 1.56 0.42 0.74 2.38
Schulze-Rauschenbach et al. 2005 [33] 1.90 0.43 1.07 2.73 1.67 0.44 0.81 2.53
O’Connor et al. 2003 [20] 0.56 0.39 −0.20 1.31 2.27 0.48 1.32 3.22
Grunhaus et al. 2003 [34] 1.54 0.36 0.83 2.25 1.93 0.38 1.18 2.68
Janicak et al. 2002 [26] 1.93 0.47 1.00 2.86 2.17 0.59 1.00 3.33
Grunhaus et al. 2000 [28] 1.49 0.36 0.79 2.19 1.90 0.38 1.16 2.65
Table 3: Combined effect sizes for fixed and random effect models.
rTMS ECT
Model Confidence interval Confidence interval
Effect size Standard error Lower Upper Effect size Standard error Lower Upper
Fixed effect 1.24 0.11 1.01 1.46 2.17 0.13 1.90 2.43
Random effect 1.28 0.15 0.97 1.58 2.15 0.16 1.85 2.46
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Figure 2: Forrest Plot rTMS.














Figure 3: Radial Plot ECT.
Publication Bias for ECT Studies.
Rosenthal File drawer Method.
Tolerance minimum number = 55.
Estimated number = 587.
Estimated not less than minimum: publication bias
not detected.
Rank Correlation.
𝑧 = −0.1043 𝑃 = 0.5415.
4. Discussion
4.1. Summary. To my knowledge, this is the first meta-ana-
lysis that set out to analyse and compare ECT, the “gold stan-
dard” treatment for severe depression, with the relatively new
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Figure 4: Forrest Plot ECT.
nine randomised controlled clinical trials were included.The
null hypothesis, that is, that there is no significant difference
in the antidepressant efficacy between the two types of
treatment modalities, was tested using a number of statistical
measures and was refuted.
4.2.Main Conclusions. The results of thismeta-analysis show
that patients who undergo either rTMS or ECT have statisti-
cally significant reductions in their depressive symptoms, as
measured byHDRS. rTMSparticipants had amean reduction
of 9.3 points whilst ECT participants had amean reduction of
15.42 points on the HDRS. This is an important conclusion,
especiallywhen one takes into account the fact that themajor-
ity of participants who were referred for the studies were
refractory to treatment with psychotropic medication. When
the degree of improvement between rTMS and ECT par-
ticipants was analysed, those participants undergoing ECT
showed significantly lower HDRS scores compared to those
undergoing rTMS. When the effect size was factored into the
comparison, the difference became even more significant in
favour of ECT. This conclusion reaffirms ECT as the leading
therapeutic modality for patients with treatment resistant
depression, purely on the basis of depressive symptomatology
outcome, but also suggests the therapeutic validity of rTMS as
a treatment tool for depression in patients who are treatment
resistant.
4.3. Individual Study Conclusions. Three of the nine studies
concluded that the antidepressant effect of ECT is signifi-
cantly larger than rTMS when the groups were compared
(Eranti et al., 2007) [27, 28]. The other studies did not report
any significant difference when both groups were compared;
however, Keshtkar et al. (2011) showed that the decrease in the
score for suicidal subscale score of HDRS was significantly
6 Depression Research and Treatment
greater in the ECT group than in the rTMS group.This meta-
analysis therefore served to confirm the results of these stud-
ies. The studies which did not show significant differences
between the rTMS and ECT participants (Grunhaus et al.,
2003; Schulze-Rauschenbach et al., 2005) [20, 26, 29] were
further analysed in order to ascertain possible causes for lack
of significant difference between the groups. The first factor
analysed was the age of participants, since Figiel et al. (1998),
Kozel & George (2002), and Pallanti et al. [30] have reported
that older patients had poorer outcome when undergoing
rTMS compared to younger patients. Interestingly, in Janicak
et al. [26], the authors observed that the younger patients
seem to need fewer rTMS treatments to achieve the response
as compared to older people. In fact, two of the three studies
which showed significant difference (Eranti et al., 2007) [28]
had the highest mean age for participants undergoing rTMS.
However, one must be cautious before making predictive
conclusions from such a correlation and further studies need
to be carried out in order to confirm such findings. Another
factor studied was the type of ECT that was administered
to patients, since it is known that bilateral ECT has better
outcomes when compared to unilateral ECT [35]. However,
no correlation was found between the studies with respect
to electrode placement in ECT participants. When looking at
the diagnosis of participants in the studies, it can be noted that
some studies had participants with only unipolar depression
[28] (Grunhaus et al., 2003; Rosa et al., 2003) whilst the rest
had patients with both unipolar and bipolar depression.
Whilst ECT is known to be effective in patients who are
in both their depressive as well as their manic phases of their
bipolar illness [36], rTMS has not been substantially studied
in such patients. This raises the question of whether rTMS
has a similar effect on bipolar and unipolar depression. At a
similar tangent, in one of the studies [28], participants with
psychotic depression showed significantly less improvement
with rTMS. This observation should therefore be addressed
in future studies. Interestingly, publication bias was not
detected, using both the Rosenthal File drawer Method as
well as Rank Correlation. This may be, in part, due to the
recent efforts of prominent medical journals that require
authors to register their trial before it begins.Therefore, unfa-
vourable results are published and not withheld.
4.4. Limitations
4.4.1. Control Groups. One of the main limitations of this
meta-analysis, which reflects the limitations of the individual
studies, is that placebo/sham groups were not used; although
the studies were randomised and controlled, a sham compar-
ison group was not used. As described by Grunhaus, this lack
of control may constitute a problem in both rTMS as well as
ECT groups: “The placebo components of rTMS (daily contact,
popular beliefs on the effects ofmagnets, etc.) could be powerful.
Similar psychological issues, however, could be in effect in the
ECT-treated patients in whom an aversion to the treatment
may constitute a strong factor for an escape into health” [28].
However, as stated by a number of the study authors, due
to the severity of the depression, it was not thought to be
ethically justifiable to have a placebo/sham group.
4.4.2. Blinding. Another important consideration which
must be taken into account is that the studies were not
blinded, both with respect to observers as well as to partici-
pants. In fact, only one of the studies was single blind with
respect to observers [29]. Even though patients were asked
not to reveal their group allocation, the strength of this
single blind remains dubious. Although the authors gave a
rationale for the lack of blinding, this still remains one of the
limitations present and should be addressed in future com-
parative studies.
4.4.3. Psychotropic Medications. In three of the studies [28]
(Grunhaus, et al., 2003, O’Connor et al., 2006), participants in
the ECT group were allowed to continue their psychotropic
medications, whilst the participants in the rTMS group were
not. The contribution that psychotropic medications had on
the outcome of these studies is therefore up for debate. In fact,
a number of studies [37, 38] have shown that a combination
treatment of rTMS and antidepressants results in a significant
improvement when compared with placebo.
4.4.4. Treatment Protocols. In some of the studies ECT was
continued until treatment response, while rTMS was admin-
istered over a predetermined schedule. As suggested by Eranti
et al. (2007) “Although the mean durations of the rTMS and
ECT courses were comparable, it could be suggested that many
more weeks of rTMS were required.” ECT dose was also
adjusted secondary to participant response and not according
to a fixed protocol in the majority of studies.
4.4.5. Definition of Response. One of the main outcomes of
the included studies was response and remission according
to HDRS scale. Response is commonly defined as a reduction
in HDRS score of 50% or more whilst remission as a final
HDRS score of eight or less [39]. Unfortunately, the studies
had varying definitions of response and remission. Hansen
et al. [27], for example, use the term partial remission as their
endpoint, whichwas equal to anHDRS score of twelve or less.
4.4.6. Definition of Treatment Resistance. As previously dis-
cussed, treatment resistance generally occurs when there is
inadequate response to at least two antidepressants [30].
However, none of the studies discussed the grade of treatment
resistance and studies did not indicate what antidepressant
treatment was tried before the patient was classified as
treatment resistant.
4.4.7. Limitations of Meta-Analysis. As previously discussed,
study participants differed with respect to age and sex dis-
tribution, drug therapy, type of depression, psychotic symp-
toms, treatment parameters, and blinding. Nevertheless, all
studies reported initial and endpoint HDRS scores, which
was one of the main criteria for admission of the study into
the meta-analysis. In addition to the limitations described
above, the main limitations of the meta-analysis were that
the studies that have been carried out (and included in this
meta-analysis) comparing rTMS and ECT are small, with a
limited number of participants (between 25 and 73) which
makes generalisation of results difficult. The main reason for
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this is that rTMS is still in its infancy when it comes to
routine clinical use, and in many places it remains an experi-
mental technique. As the use of rTMS gains traction, further
studies, with larger sample populations, will allow further
investigation of the benefits of rTMS, and therefore a better
comparison with ECT can take place.
4.4.8. HDRS. Another limitation to consider is the use of
the HDRS. A number of studies have criticised the scale’s
ability to measure the severity of the patient’s depression and
have concluded that the scale suffers from poor retest and
inter-rater reliability, poor content validity, as well as poor
replication across samples [40, 41].
4.5. Future Work. As a result of the limitations listed above,
a number of improvements should be sought in future meta-
analyses. However, since many of the limitations are due to
the design of the studies themselves, this will add a degree of
difficulty for subsequent meta-analyses to overcome. Future
work on the effects of patient age and diagnosis of uni-
polar versus bipolar depression, when comparing the two
treatment modalities, would help to shed further light onto
the significant difference found in this meta-analysis. Com-
parison of the short term and long term side effects would
also be an essential step in the risk/benefit analysis of the two
treatment modalities, allowing clinicians to select the most
appropriate modality for particular patients.
4.6. Concluding Remarks. In conclusion, this report compar-
ing the effects of rTMS and ECT in the treatment of depres-
sion, whilst showing ECT’s superiority when compared
directly to rTMS, also shows that rTMS can be considered
as a useful adjunct to the therapeutic interventions in depres-
sion currently available. Whilst not proving beyond reason-
able doubt the efficacy of rTMS, this meta-analysis indicates
an important role for rTMS in the management of treat-
ment resistant depression, especially in select patient groups.
However, the future success and deployment of this treatment
modality will largely be contingent upon further technolog-
ical as well as logistical advances that can help to clarify
effective use, cost-effectiveness, access to treatment, and
patient selection.
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